Impact of myocardial revascularization on long-term outcomes in a nationwide cohort of first acute myocardial infarction survivors
Open Access
- 18 May 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 24 (Supplement) , C225-C232
Abstract
The long-term clinical benefits of myocardial revascularization in a contemporary, nationwide cohort of acute myocardial infarction (AMI) survivors are unclear. We aimed to compare the mortality rates and clinical outcomes at 8 years of patients admitted in Italy for a first AMI managed with or without myocardial revascularization during the index event. This is a national retrospective cohort study that enrolled patients admitted for a first AMI in 2012 in all Italian hospitals who survived at 30 days. The outcomes of interest were all-cause mortality, major cardio-cerebrovascular events (MACCE), and re-hospitalization for heart failure (HF) at 8 years. Time to events was analysed using a Cox and Fine and Gray multivariate regression model. A total of 127 431 patients with AMI were admitted to Italian hospitals in 2012. The study cohort consisted of 62 336 AMI events, of whom 63.8% underwent percutaneous or surgical revascularization ≤30 days of the index hospital admission. At 8 years, the cumulative incidence of all-cause death was 36.5% (24.6% in revascularized and 57.6% in not revascularized patients). After multiple corrections, the hazard ratio (HR) for all-cause mortality in revascularized vs. not revascularized patients was 0.61 (P < 0.0001). The rate of MACCE was 45.7% and 65.8% (adjusted HR 0.83; P < 0.0001), while re-hospitalizations for HF occurred in 17.6% and 29.8% (adjusted HR 0.97; P = 0.16) in AMI survivors revascularized and not revascularized, respectively. In our contemporary nationwide cohort of patients at their first AMI episode, those who underwent myocardial revascularization within 1 month from the index event compared to those not revascularized presented an adjusted 39% risk reduction in all-cause mortality and 17% in MACCE at 8-year follow-up.Keywords
This publication has 27 references indexed in Scilit:
- Long-Term Survival and Recurrence After Acute Myocardial Infarction in England, 2004 to 2010Circulation: Cardiovascular Quality and Outcomes, 2012
- Regional Patterns of Use of a Medical Management Strategy for Patients With Non–ST-Segment Elevation Acute Coronary SyndromesCirculation: Cardiovascular Quality and Outcomes, 2012
- Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary SyndromesNew England Journal of Medicine, 2012
- Predicting long-term mortality in older patients after non–ST-segment elevation myocardial infarction: The CRUSADE long-term mortality model and risk scoreAmerican Heart Journal, 2011
- Primary angioplasty vs. fibrinolysis in very old patients with acute myocardial infarction: TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos) randomized trial and pooled analysis with previous studiesEuropean Heart Journal, 2010
- Influence of Age on Use of Cardiac Catheterization and Associated Outcomes in Patients With Non-ST-Elevation Acute Coronary SyndromesThe American Journal of Cardiology, 2009
- Strategies for Reducing the Door-to-Balloon Time in Acute Myocardial InfarctionNew England Journal of Medicine, 2006
- Interventional versus conservative treatment in acute non-ST elevation coronary syndrome: time course of patient management and disease events over one year in the RITA 3 trialHeart, 2006
- Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trialsThe Lancet, 2003
- Bias in the Coding of Hospital Discharge Data and Its Implications for Quality AssessmentMedical Care, 1994